HomeAI · summaries
Storia in 5 fonti
Regenxbio hit with another clinical hold for Hunter syndrome gene therapy
Regenxbio's RGX-121 Hunter syndrome gene therapy faces second clinical hold after spinal lumps found in 5 CAMPSIITE trial patients, sending $RGNX shares down 23%.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.
- ·
morningstar.com
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
